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AD Alzheimer's disease 
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EEC European Communities Council 
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f d a Food and Drug Administration 
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f r f i d s Phe-Arg-His-Asp-Ser 
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g g g g g Pentaglycin 
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LPYFDa Leu-Pro-Tyr-Phe-Asp amide 
LRP Low density lipoprotein receptor-related protein 
LTP Long term potentiation 
LVFFA Leu-Val-Phe-Phe-Ala 
mAP Monoclonal antibody against AP 
mGluR Metabotropic glutamate receptor 
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MIP-1 a Macrophage inflammatory protein-1 a 
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MRI Magnetic resonance imaging 
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NIH National Institutes of Health 
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t Tau protein 
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The leading cause of senile dementia among the elderly is Alzheimer's disease (AD). 
Nearly 3% of people aged 65 show signs of the disease, while 25-50% of people aged 85 have 
symptoms of this progressive mental deterioration, and estimates place the number of affected 
individuals to 29 million by 2020. The incidence of AD increases exponentially with age and 
there is no leveling off in very old age (at least up to the age of 90) (Jorm and Jolley, 1998). If 
mild cases are included, the prevalence is as high as 10.3 % in a western population over 65 
years of age and increases to almost 47 % for people over 85 years of age. In the 85+ group, 
the disease is most prominent in females (ratio 2.8/1 over 75 years of age) (Forsyth and 
Ritzline, 1998). Although by 2050 the number of people affected with AD will be doubled, an 
effective treatment for the disease is still lacking. 
In 1907, Alois Alzheimer was the first to describe a form of dementia in a 55-year old 
female of which post mortem staining of the brain - with at that time newly available silver 
stains - revealed the presence of tangled fibres and clusters of degenerating nerve endings 
(Katzman, 1986). Furthermore, Alzheimer described progressive memory impairment, 
disordered cognitive functions, altered behavior (paranoia, delusions) and decline in language 
function, all features that are still identifiable in Alzheimer patients today (Selkoe, 2001). This 
collection of symptoms came to bear his name and is nowadays still a topic of extensive 
research. The histological identifiable hallmarks of AD are: 1) intraneuronal, cytoplasmatic 
deposits of neurofibrillary tangles (NFT), 2) extracellular amyloid deposits called neuritic 
plaques, 3) cerebrovascular amyloidosis and 4) synaptic loss (Wisniewski et al., 1997). 
The underlying cause of the disease is still in debate. A vast amount of data fortifies 
the widely accepted amyloid cascade hypothesis. In contrast, the direct link between amyloid 
deposition and loss of cognitive functions has not been proven convincingly yet. However, an 
alternative theory which covers the cause and the onset of AD and is experimentally 
supported has not emerged so far. 
Neuropathological features 
Atrophy 
Post mortem studies show brain volume of AD patients is 10 - 25 % lower than the 
average volume of control subjects without the disease (de la Monte, 1989; Hubbard and 
Anderson, 1981). The loss of brain tissue involves both neocortex and cerebral white matter, 
with the white matter atrophy presumably being a secondary event characterized by a partial 
loss of myelin sheaths, axons and oligodendroglial cells (Brun and Englund, 1981). Not all 
brain regions are affected with the same severity. Atrophy in AD is most severe in the 
temporal lobe, particularly in the medial temporal lobe. The accelerated atrophy of the 
temporal neocortex, not the hippocampus, in AD patients is associated with a symptomatic 
onset of dementia (Convit et al., 2000), whereas atrophy of the hippocampus occurs 1 to 2 
years before dementia onset (Convit et al., 1997; Fox et al., 1996). The cholinergic subcortical 
nucleus, nucleus basalis of Meyert is one of the areas that being affected earliest in AD 
(Toledano and Alvarez, 2004). 
Amyloid plaques 
The best known histological hallmark of AD is the presence of senile plaques (SP) that 
are found in the brain of patients suffering from AD. SPs show a topographic distribution that 
bares some relationship to the stage of the disease. The earliest affected regions are 
neocortical association areas, especially in temporal and parietal lobes. The amygdala and 
hippocampus show relatively little amyloid deposition in the early stage of the disease. As the 
disease progresses, extracellular deposits of amyloid without associated dystrophic neuritis 
{i.e. diffuse plaques) accumulate in the hippocampal dentate gyrus and neostriatum. 
Neuritic plaques consist mainly of aggregated amyloid p, but both 1-40 (> 60 %- 70 
%) and 1-42 (<15 %) forms are found, together with minor amounts of other p-amyloid 
peptides (AP1-28, Api-33, Api-34, AP3-34, Api-37, Api-38, Api-39) (Golde et al., 2000). 
Dystrophic neurons are to be found within the amyloid deposits and immediately surrounding 
them. These neurons are often dilated and are marked with ultrastructural abnormalities such 
as enlarged lysosomes, numerous mitochondria and paired helical filaments or neurofibrillary 
tangles. These neuritic plaques are also intimately associated with microglia expressing 
surface antigens associated with activation and are surrounded by reactive astrocytes 
displaying abundant microglial filaments (Dickson, 1997). The microglia are usually within 
and adjacent to the central amyloid core of the neuritic plaque, whereas the astrocytes often 
surround the outside of the plaque (Selkoe, 1994). Although numerous proteins are associated 
/ > 
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with the amyloid deposits in AD, the principal proteinaceous component of the plaque core 
are aggregates of a <4 kDa polypeptide (Glenner and Wong, 1984), proteolytically derived 
from a large transmembrane amyloid-P precursor protein (ApPP). APPP is a single 
transmembrane protein that is cotranslationally translocated into the endoplasmatic reticulum 
of the cell via its signal peptide and then post-translationally modified through the secretory 
pathway. Its half-life is relatively short (-45-60 minutes) (Weidemann et al., 1989). During 
the trafficking through the secretory pathway, ApPP can undergo a variety of proteolytic 
cleavages to release secreted derivatives into vesicle lumens and the extracellular space. 
The role of ApPP is under extensive research, however, not fully understood yet. The 
ApPP splice forms of 751 and 770 amino acids are widely expressed in nonneuronal cells 
throughout the body and also occur in neurons. The 695-residue form is mainly expressed in 
neuronal cells (Selkoe, 2001). The ApPP of 751 and 770 amino acids contains a 56-residue 
insert in the middle of the ectodomain encoding a Kunitz-type serine protease inhibitor (KPI). 
In vitro studies confirm that these isoforms can inhibit serine protease such as trypsin and 
chymotripsin (Sinha et al., 1990). ApPP is able to bind Zn(II) and Cu(II). Zn(II) increases 
binding of ApPP to heparin and has been shown to potentiate the inhibition of coagulation 
factor XIa by an ApPP isoform containing a Kunitz-type inhibitory domain (Bush et al., 1993; 
Smith et al., 1990). ApPP is able to catalyze a reduction of Cu(II) to Cu(I), thus protecting the 
neuron from potential formation of reactive oxygen species in the presence of Cu(II) 
(Barnham et al., 2003). A small stretch of amino acids containing the Arg-Glu-Arg-Met-Ser 
sequence (ApPP328-332) C-terminal to the KPI insertion site has been identified as the active 
domain responsible for growth promotion and neurite extension in neural cells (Jin et al., 
1994; Roch et al., 1994) and for neuronal survival (Yamamoto et al., 1994). It appears that 
ApPP also is required during an early phase of memory formation (Mileusnic et al., 2000). 
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Fig. 1. Schematic diagram of AfiPP. Regions of interest (at their correct relative position) : the 
17-residue signal peptide at the NH2 terminus (box with vertical lines), two alternatively 
spliced exons of 56 and 19 amino acids inserted at residue 289 (the first is the KPI domain), 
the single transmembrane domain (TM) at amino acids 700-723 (vertical dotted black lines). 
Arrowheads indicate the cleavage sites of a-, J3- and y-secretase. Figure adapted from: 
(Selkoe, 2001). 
Neurofibrillary tangles 
Another typical hallmark of AD is the presence of paired helical fragments (PHFs), or 
neurofibrillary tangles, composed of the microtubule-associated protein tau (T) in a 
hyperphosphorilated form, as revealed by immunocytochemical and biochemical analyses. 
NFTs are mostly found in the nerve cells, accumulating in perikaryon, dendrites and axons 
(Brion, 1998), but as they are persistent structures following cell death, they are also found 
extracellularly. The majority of neurons in the typically affected AD brain regions (entorhinal 
cortex, hippocampus, parahippocampal gyrus, amygdala, frontal, temporal, parietal and 
occipital association cortices and certain subcortical nuclei projecting to these regions) 
contain large, non-membrane-bound bundles of abnormal fibres that occupy much of the 
perinuclear cytoplasm (Selkoe, 2001). Ultrastructurally, these fibres consist of pairs of 
approximately 10 nm filaments wound into helices with a helical period of -160 nm as 
revealed by electron microscopy (Yankner and Mesulam, 1991). 
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The amyloid cascade hypothesis 
The most widely accepted theory concerning the aetiology of AD is the amyloid 
cascade hypothesis (Hardy and Selkoe, 2002; Hardy and Higgins, 1992). This theory proposes 
Ap as the central trigger of the pathological changes observed in the brains of AD patients, 
such as synaptic loss, activation of inflammatory processes, the induction of neurofibrillary 
changes leading to the formation of PHF and, ultimately, neuronal death. 
The APPP can be processed by two different pathways: a conventional pathway that 
does not lead to the release of Ap and an alternative pathway, leading to an augmentation of 
the amount of Ap fragments that are prone to aggregate (Haass and Selkoe, 1993). Three 
proteases play an important role in the normal and pathological processing of ApPP, i.e. a-
secretase, p-secretase and y-secretase. a-secretase is of the family of proteases that process 
other integral membrane proteins such as transforming growth factor-a and tumor necrosis 
factor-a (Blacker et al., 2002). It consists of a constitutive component and a regulated 
component that can be activated via protein kinase C and other second messenger cascades. 
Several members of the disintegrin and metalloprotease family (ADAM) have been 
implicated in ApPP-processing: TNF-a converting enzyme (Buxbaum et al., 1998), ADAM 10 
and ADAM9 (Hotoda et al., 2002) and ADAM 17 (Asai et al., 2003). Cleavage by a-secretase 
is the first step in the non-pathological proteolytic processing of APPP. The a-secretase 
cleaves between Lysl6 and Leu 17 (residues 612 and 613 of ApPP 1-695) in the sequence that 
produces the Ap itself (Esch et al., 1990), and therefore preludes generation of the Ap peptide. 
Processing of ApPP by a-secretase releases a soluble fraction, called aAPPs and leaves an 83 
amino acid residue in the cell membrane. The aAPPs might have biological functions in 
growth regulation and neuroprotection, and in the case of isoforms containing the Kunitz 
proteinase inhibitor domain, in blood coagulation (Van Nostrand et al., 1992). 
p-secretase is a type-1 transmembrane protein containing aspartyl protease activity that 
cleaves ApPP at the N terminus of the Ap sequence and is the first prerequisite for generation 
of Ap, peptides. One enzyme has been identified as the p-secretase, namely BACE-1 (p-site 
ApPP-cleaving enzyme). Homozygous knockout mice of the BACE-1 gene do not show any 
generation of Ap, indicating that this enzyme is indeed the major one with p-secretase activity 
(Cai et al., 2001). Besides cleavage at the beginning of the Ap sequence, it also cleaves at 
Glul 1, releasing a shorter form of the AP peptide previously identified in plaques (Masters et 
al., 1985). A close homolog of BACE-1, BACE-2 was identified as well, but this exhibits an 
a-secretase activity because it cleaves in the middle of the AP-domain between 
phenylalanines 19 and 20 (Fluhrer et al., 2002). The normal physiological substrate of BACE-
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1 is not accurately known. Candidates include the low density lipoprotein receptor-related 
protein (LRP) (von Arnim et al., 2005), ApPP like proteins (APLP1 and -2) (Li and Sudhof, 
2004), P-selectin glycoprotein ligand-1 (PSGL-1), and a membrane-bound sialyltransferase 
(Kitazume et al., 2001). 
y-secretase, which is able to cleave ApPP in the intramembrane part of the protein 
consists of a complex of four proteins: presenilin, nicastrin, Aph-1 (anterior pharynx-defective 
phenotype), Pen-2 (presenilin enhancer) (De Strooper, 2003). The presenilins (PS1 and PS2) 
appear to provide the active core of the protease, but are not sufficient for the proteolytic 
activity. Mutations in the PS gene can cause the early-onset form of AD by shifting the 
cleavage site of ApPP two amino acids towards the C-terminus, causing an increase in the 
Api-42/Apl-40 ratio and thereby enhancing oligomer formation of amyloidogenic Apl-42. 
Neuronal cultures derived from PS1 knockout mice showed a severely reduced Ap generation 
(De Strooper et al., 1998), and when the PS2 gene was eliminated as well, no Ap generation 
was observed at all (Herreman et al., 2000; Zhang et al., 2000). Further proof of the 
importance of the presenilins in y-secretase activity came from the observation that all 
presenilins contain two functionally important and highly conserved aspartate residues within 
transmembrane domains 6 and 7. As y-secretase belongs to the aspartyl protease family, the 
hypothesis that the presenilins and y-secretase were the same, or at least that the presenilins 
were a constituent of y-secretase, was brought up. Indeed, when either of the two aspartates 
was mutagenized, AP generation was abolished (Wolfe et al., 1999). A cofactor identified 
from the purified complex is nicastrin (Yu et al., 2000). It is a type 1 transmembrane 
glycoprotein which interacts with both PS1 and PS2, and which has a central role in 
presenilin-mediated processing of ApPP and some aspects of Notch/glp-1 signaling in vivo. 
When nicastrin was down-regulated in cultured cell lines using small interfering RNA, a 
massive accumulation of C-terminal fragments of ApPP was seen, together with a marked 
reduction of Ap production (Edbauer et al., 2002). Two multipass membrane proteins were 
isolated during genetic screening for enhancers of a PS-dependent Notch-deficient phenotype 
in Caenorhabditis elegans: Aph-1 and Pen-2 (Francis et al., 2002; Goutte et al., 2002). 
Besides cleavage of APPP, y-secretase is able to process other integral membrane proteins, 
such as Notch-1 (Moehlmann et al., 2002; Nakajima et al., 2000; Song et al., 1999), which 
plays a role in gene transcription and cell differentiation, N-cadherin (Marambaud et al., 
2003), and ephrinB2 (Georgakopoulos et al., 2006). 
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Formation and neurotoxicity of Af species 
The normal physiological pathway of ApPP processing is the secretory pathway, in 
which APPP is first cleaved by a-secretase and subsequently by y-secretase. The first 
proteolytic cleavage identified is that made by a-secretase and this occurs at 12 amino acids 
from the amino-terminal of the single transmembrane domain of ApPP (Esch et al., 1990; 
Sisodia et al., 1990) which results in the release of a large soluble ectodomain fragment called 
a-APPs. The 83-amino acid COOH-terminal fragment (CTF or plO) may undergo an 
additional cleavage by y-secretase, resulting in the formation of p3 and its complementary 
product p7. The pathological pathway in which ApPP can be processed is the endosomal-
lysosomal pathway (Nixon et al., 2000). APPP is first cleaved by p-secretase to form the N-
terminus of Ap at the Asp+1 residue of the Ap sequence. Two cleavage products are formed: 
a secreted soluble ectodomain of ApPP, named pAPPs, and the C99 fragment (Vassar, 2001). 
C99 is further processed by y- secretase at several positions between amino acid 39 and 43 of 
the Ap sequence. The physical properties and the aggregation behavior of the end-products 
depend on their length (Burdick et al., 1992). 
Initially, investigators proposed that fibrillar Ap accumulation triggered a pathological 
cascade that ultimately produced the complete pathological and clinical symptoms of AD. 
Nowadays it is less clear whether Ap, deposited as amyloid or some less well characterized p 
aggregate, initiates the cascade leading to neuronal death and dysfunction. Indeed, small Ap 
oligomers, also referred to as AP-derived diffusible ligands (Klein, 2002) have been put 
forward as alternative aggregated forms of Ap that may mediate toxicity. A recent report, 
which was received wide publicity, describes Ap*, a 56 kDa 12-mer Apl-42 aggregate, as the 
ultimate cause for cognitive decline (Lesne et al., 2006). There is also some evidence that 
intracellular accumulation of AP may be neurotoxic (Gouras et al., 2000). To make the picture 
less clear, recently an alternative aggregation pathway resulting in stable, globular oligomeric 
species was proposed (Barghorn et al., 2005). 
The Ap-induced pathological cascades leading to neuronal dystrophy and death are not 
as well defined as the pathways leading to Ap generation. Multiple pathways are likely to 
mediate Ap toxicity. There is evidence that Ap can be directly neurotoxic, induce oxidative 
stress, alter calcium homeostasis and incite an inflammatory response in which all typical 
features of an inflammatory response to an insult are present: There is activation of the 
complement system, the concentration of chemokines and cytokines such as IL-lp, IL-6, 
TNF-a, TGF-p and macrophage inflammatory protein-la (MIP-la) seem to be upregulated, 
the level of cyclooxygenase-2 (COX2) is increased in AD brain and there is an increased p2-
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integrin LFA-1 expression by microglia cells, as well as other acute phase proteins (Akiyama 
et al., 2000). These events might be mediated by direct interaction of Ap aggregates with 
cellular membranes or by the binding of Ap to microglial and neuronal cellular receptors. 
Indeed, Api-42 is able to bind to several neuronal membrane proteins (insulin receptor, serpin 
complex receptor, a7 nicotinic acetylcholine receptor, integrin pi, receptor for advanced 
glycosylation end products, collagen-like Alzheimer amyloid plaque component precursor, N-
methyl-D-aspartate receptor, ApPP, P75 neurotrophin receptor) (for review, see (Verdier et 
ah, 2004). Once internalized, Ap has been shown to bind to numerous vital housekeeping 
enzymes (Verdier et ah, 2005). 
Luriftn or extracellular 
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Fig. 2.: Proteolytic processing of AfPP by the secretases. The majority of APP is processed 
in the nonamyloidogenic pathway (thick arrow); APP is first cleaved by a-secretase within 
the Aft domain (darker shaded region), leading to APPsa secretion and precluding Af 
generation, a-carboxy terminal fragment (CTF) is then cleaved by y-secretase within the 
membrane, releasing the p3 peptide and AICD. Alternatively, amyloidogenesis (thin arrow) 
takes place when AfPP is first cleaved by f-secretase, producing APPsf. Af and AICD are 
generated upon cleavage by y-secretase of the fi-CTFfragment retained in the membrane. 
Scissors indicate the cleavage sites of a-, [1- and y-secretase. Figure from (Wilquet and De 
Strooper, 2004). 
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Data supporting the amyloid cascade hypothesis 
Several pieces of evidence support the amyloid cascade hypothesis: first, people with 
mutations in the ApPP, PS 1 and PS2 genes are associated with elevated levels of Ap proteins 
(Scheuner et al., 1996), suffering from the inherited form of AD, suggesting that Ap plays an 
important role in the onset of the disease. Moreover, patients with trisomy 21 (Down's 
syndrome) virtually all develop senile plaques and by the age of 40 have sufficient 
neuropathology for a diagnosis of AD (Head and Lott, 2004). These patients all have 3 alleles 
of chromosome 21 in each cell, which leads to a higher level of Ap proteins, as the gene 
encoding for ApPP and the gene encoding for one of the enzymes responsible for the cleavage 
of ApPP into the amyloidogenic sequence is located on gene 21 (Barbiero et al., 2003). In 
contrasts, in a patient with Down's syndrome but with only two copies of the gene sequence 
for ApPP, no evidence of Alzheimer's disease was found on neuropsychological, MRI and 
neuropathological assessment (Prasher et al., 1998). Second, a wealth of literature data reports 
that aggregated assemblies of Api-40 and Api-42 can damage neurons in vitro and in vivo. 
Furthermore, inhibitors of Ap aggregation attenuate the neurotoxicity (Du et al., 2003; 
Permanne et al., 2002; Soto et al., 1998). Not only neurons may be damaged by Ap peptides. 
Monocytes incubated with Ap show a neurocytopathic effect on rat brain cells, indicating that 
inflammatory reactions in the brain, triggered by Ap, play a role in the neurodegeneration that 
accompanies AD (London et al., 1996). In addition, Ap activates the complement immune 
system (Rogers et al., 1992) and microglia (Giulian et al., 1995). Transgenic mice 
overexpressing ApPP display at an early age typical amyloid plaques in their brain, which 
resemble those found in brain of AD-patients (Terai et al., 2001). These mice also show 
clinically typical features found in AD patients: they have a marked cognitive impairment 
with decreased long term potentiation, aggression and neophobia (Moechars et al., 1999). 
Furthermore, if proteolysis of Ap is enhanced in these mice, plaque formation and the 
secondary pathology are prevented (Leissring et al., 2003). 
Data against the amyloid cascade hypothesis 
Transgenic animals are commonly used for studying AD. The most widely used 
Tg2576 line overexpresses human APPP containing the double Swedish mutation 
K670NM671L. Tg2576 mice develop cerebral Ap deposits and spatial memory deficits in an 
age dependent manner, however no neurofibrillary tangle formation or significant neuronal 
loss in CA1 (Hsiao et al., 1996; Irizarry et al., 1997). Recently, a triple Tg model published by 
Oddo and coworkers based on comparable overexpression of mutant human APP, PS1 and tau 
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has been published, which develops early deficits in long-term synaptic plasticity that 
correlate with accumulation of intraneuronal Ap followed by amyloid plaques and NFT 
formation in an age-dependent fashion (Oddo et al., 2003). Interestingly, extracellular Ap 
{ 
deposition precedes tau pathology by several months in this latter Tg line, which seems to 
favor the amyloid cascade pathogenic hypothesis. However, no human yet has been found 
I 
carrying these triple mutations. 
The exact molecular mechanism by which FAD-linked PS1 pathogenic mutations 
affect ApPP processing in the diseased human brain, or even in cell culture or animal models 
is still in debate. A consensus about the near one dozen FAD linked point mutation in PS1 
leading to increased in y-secretase efficiency; therefore increased Apl-42 production seems 
difficult to reach. Several results support the notion that some of these mutations lead to a 
severe loss of catalytic function, as was shown for the y-secretase cleavage of N-cadherin 
(Marambaud et al., 2003), Notch-1 (Moehlmann et al., 2002; Nakajima et al., 2000; Song et 
al., 1999), and ephrinB2 (Georgakopoulos et al., 2006). A similar apparent loss-of-function 
mechanism was also reported for ApPP processing at the s-cleavage site (Bentahir et al., 
2006; Chen et al., 2002; Wiley et al., 2005). 
There are more than 20 different dementing disorders (tau pathology, or tauopathy), 
where neurofibrillary degeneration manifests without the formation of amyloid plaques 
(Delacourte and Buee, 2000). Although the aggregation of intracellular tau seems important in 
these dementias, the role of diffusible AP species, which are difficult to investigate in a post 
mortem brain material, cannot be ruled out. In addition, the amount of amyloid load does not 
always correlate with the cognitive decline in AD patients (Mufson et al., 1999; Nagy et al., 
1995). 
Treatment nf Alzheimer's disease: current and future therapies 
Drugs currently used in the therapeutic scheme of AD patients are all symptomatic and 
none of them actually cures the disease. Until now, no cure has been found, but extensive 
Progression has been made throughout the last five years, which will hopefully lead to an 
effective cure. 
Donepezil (Aricept®), galantamine (Reminyl®) and rivastigmine (Exelon®) are all 
cholinesterase inhibitors which lead to an increase of acetylcholine in the brain and therefore 
can aid the patient (Cutler and Sramek, 2001). These products stabilize the memory decline 
for a variable period (typically 6 to 12 months). These drugs are effective in delaying the 
deteriorating symptoms in patients with mild to moderate AD, but are not effective any more 
in the end. The clinical usefulness of these drugs is doubtful, but to date these are the only 
f 
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products that can influence the progress of the disease in an early stage. Since AD is often 
accompanied by symptoms of depression and anxiety, anti-depressants and anxiolytics are 
frequently added to the therapeutic scheme of the patient. 
Psychotropic medications play a critical role in the management of behavioral 
disturbances of patients with AD. Relatively few psychotropic compounds have been tested 
specifically in AD populations. Recent double-blind, placebo-controlled trials have 
established the efficacy of the atypical antipsychotics risperidone and olanzapine for the 
treatment of psychosis and agitation in patients with AD (Street et al., 2001). Vitamin E and 
selegiline have been shown to reduce the rate of decline of functions in patients with AD. 
Evidence to support the use of other antioxidants, anti-inflammatory agents, or herbal 
medications such as Ginkgo biloba is insufficient to recommend use as standard therapies 
(Luo, 2001). Estrogen in high doses has been shown to improve cognition in postmenopausal 
women with AD (Asthana et al., 2001). 
Blocking N-methyl-D-aspartate (NMDA) receptor is an other approach in the current 
treatment of AD. Memantine is a new symptomatic drug that recently has been approved by 
the FDA. It is a noncompetitive NMDA receptor antagonist which, after binding to the 
postsynaptic NMDA-receptors, can prevent glutamate excitotoxicity which leads to neuronal 
calcium overload and ultimately to cell death (Wilkinson, 2001), but does not prevent 
physiological activation of the receptor. 
On the other hand, Weggen et al. reported that administration of certain non-steroidal 
anti-inflammatory drugs (NSAID) in the appropriate doses, leads to a reduction in Api-42 
formation independently of their influence on cyclooxygenase activity (Weggen et al., 2001). 
Flurbiprofen is a NSAID consisting of two enantiomers able to lower Apl-42 in vivo by 
targeting y-secretase (Eriksen et al., 2003). By using only the R enantiomer of the drug, R-
flurbiprofen retains the amyloid lowering ability without the accompanying COX inhibition 
and related ulcer-causing effects. Doses used to obtain this effect are very high and further 
research is necessary to obtain more accurate data on this matter. 
All these therapies remain symptomatic and do not eliminate the cause of the disease, 
namely the wrong splicing of APPP and subsequent deposition of Ap in plaques. New 
therapies that interfere with this process are momentarily being investigated. One example is 
the use of induction of Ap immunity (Frenkel et al., 2000; Schenk et al., 1999; Schenk et al., 
2000). Injecting transgenic AD mice with the purified Ap protein leads to the development of 
antibodies against amyloid protein. Studies showed that this immunization therapy not only 
inhibited the generation of new plaques, but could even lead to the removal of already 
existing plaques (Schenk et al., 1999). DeMattos and coworkers (DeMattos et al., 2002) 
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showed that the peripheral administration of a monoclonal antibody (m266) which is directed 
against the central domain (residues 13-28) of Aß 1-42, can reduce the cerebral Aß burden in 
mice. Active immunization with synthetic intact Aß 1-42 or conjugated fragments of Aß42 has 
also been evaluated in humans while techniques for passive immunization with human anti-
Aß monoclonal antibodies (mAß) are approaching clinical development. Phase II clinical 
trials of the active immunization study had to be halted because some patients developed fatal 
aseptic meningo-encephalitis (Orgogozo et al., 2003). 
Blocking of ß- and/or y-secretase is an option, which is being pursued by several 
groups, however the biological function of BACE-1 has not yet been determined and the 
question arises which unwanted consequences blocking BACE-1 will have. However, in 
BACE-1 knock-out mice, there is no generation of any Aß and these mice appear to be 
healthy without perceivable neurological or behavioral abnormalities (Luo et ah, 2001; 
Roberds et ah, 2001). In contrast, blockade of gamma secretase caution is needed because of 
its function in Notch processing which is of great importance for cell survival. Notch 
signaling pathway does play very important role in cell fate decisions during embryogenesis, 
and in adult life, as it regulates haematopoiesis (Suzuki and Chiba, 2005), neurite outgrowth 
and maintenance (Berezovska et ah, 1999). Full blockade of y-secretase will certainly 
interfere with this pathway. 
Since the underlying cause of the disease seems to be the aggregation of the misfolded 
Aß protein species, approaches targeting the folding process and aggregation may be 
beneficial. Aß peptides undergo a conformational change from the soluble a-helical/random 
coiled structure to a self aggregation-proned ß-hairpin structure. Stabilizing the a-helical 
conformation, or destabilizing the ß-sheet structure is of great promise. Indeed, there are 
several compounds, called ß-sheet breakers or amyloid aggregation inhibitors (BSB, AAI 
(Talaga, 2001)). Two main types of BSB's are known currently: non-peptide and peptide-
based compounds. Non-peptide BSB's are generally planar molecules with a hydrophobic bi-
or tricyclic scaffold. Among them, there are natural biomolecules, like melatonin (Pappolla et 
ah, 1998), nicotine (Salomon et ah, 1996), curcumin (Ono et ah, 2004; Yang et ah, 2005), or 
artificial compounds, like 4'deoxy-4'iodorubicin derivates (IDX, (George and Howlett, 1999), 
benzofuran derivates, (Howlett et ah, 1999), and the antibiotic rifampicin (Tomiyama et ah, 
1994). The native sequence of Aß 16-21, KLVFFA has been reported to be a key element of 
the aggregation process (Hilbich et ah, 1992; Tjernberg et ah, 1999), therefore peptide-based 
BSB's are based mainly on this part of Aß molecules. Tjernberg et ah published the AAI 
effect of KLVFF fragment (Tjernberg et ah, 1996). Soto et ah modified the LVFFA sequence- > 
to LPFFD, which proved to interfere with the aggregation of A|31-42 (Soto et ah, 1996;. Soto 
ö 
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et al., 1998). Studies have shown that fragment Ap31-35 also plays an important role in the 
toxicity of Afll-42 (Yan et al., 1999). An analogue of AP30-34 was able to protect against the 
intracellular Ca2+ level increasing effect of Api-42 in vitro (Laskay et al., 1997). However, 
these compounds have to be selective to the toxic forms of amyloid assemblies, since non-
toxic aggregates have been reported in mammals recently (Fowler et al., 2006). 
A short overview of glutamate receptors 
The excitatory amino acids glutamate (Glu) and aspartate are the most abundant of all 
amino acids in the brain, and are known to elicit fast excitatory responses in neurons in 
various species. The neurotransmitter nature of these amino acids is now widely recognized, 
being the principal neurotransmitter for fast excitatory signaling in brain. Glutamate is a non-
essential amino acid that does not cross the blood-brain barrier. Glu is synthesized directly in 
the brain from a-ketoglutarate in the mitochondrial compartment of Glu-erg nerve terminals 
either through transamination of aspartate or by conversion from glutamine (for review see 
(Tapiero et al., 2002). Glutaminergic neurotransmission is terminated by Glu uptake into 
neurons or glial cells through specific Glu transporters, namely excitatory amino acid carriers 
( E E A T ' S (Shigeri et al., 2004). The receptors of Glu are regarded to be almost ubiquitous 
(Orrego and Villanueva, 1993), and may be divided into two large families: metabotropic 
(mGluR) and ionotropic Glu receptors. The mGluR's are G-protein coupled and eight receptor 
subtypes have been cloned so far (mGluRl-8, (Pin and Acher, 2002). 
Ionotropic EAA receptors are multi-subunit transmembrane proteins that consist of a 
conducting pore embedded in the cell membrane and various binding sites on the extracellular 
surface of the receptor. The ionotropic receptors are named after the specific agonist to which 
they respond. The a-amino-3-hydroxy-5-methyl-isoxazole proprionic acid (AMPA) receptor, 
formerly known as the quisqualate receptor, is associated with a cation channel that is 
nonselective with respect to Na+ and K+ ions. Furthermore, it has a certain degree of Ca2+ 
permeability which is determined by the GluR2 subunit (Jonas et al., 1994). AMPA receptor 
mediated currents exhibit fast kinetics; with rapid onset, offset and desensitization. The 
AMPA receptors are widely distributed in the brain, with high density in the hippocampus and 
olfactory tubercle (Petralia and Wenthold, 1992). This receptor subtype is considered to be 
major mechanism for fast excitatory signaling in the brain (Wisden and Seeburg, 1993). 
Currently there are four different subunits described for AMPA receptors termed GluRl 
through GluR4, each of which occurs in two variants, "flip" and "flop" which are the result of 
alternative gene splicing. Kainate receptors are similar in ion gating and kinetics to AMPA 
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receptors and may be formed from five subunits designated GluR5, GluR6, GluR7, KA1 and 
KA2. (Petralia et al., 1994a). 
The N-methyl-D-aspartate (NMDA) receptors exhibit comparatively slower kinetics 
than AMPA and kainate receptors and also show significant permeability to Ca2+ ions in 
addition to Na+ and K+. NMDA receptors may be composed of various subunits, e.g. NR1 and 
NR2A-NR2D. Activation of NMDA receptors by glutamate has been shown to require 
concomitant binding of glycine to a specific glycine binding site. In addition, NMDA 
2+ , 
receptors are blocked by relatively low concentrations of Mg via interaction with a binding 
site within the ion channel complex, and a certain level of depolarization is needed for the 
Mg2+ block to be removed. The NMDA receptors are widely distributed in brain, with high 
densities found in cortical regions and hippocampus (Petralia et al., 1994b). All of these 
receptors play a key part in the processes of synaptic plasticity, like long term potentiation 
and long term depression. 
NMDA Kainate AMPA 
¿ K * * « * m* 
Fig. 3.: Schematic drawing of the three major types ofionotropic glutamate receptors. Figure 
adapted from Kandel et al., 1991 . 
Aims 
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The main goal of this Ph.D. work was to elucidate the effect of Apl-42 on synaptic 
transmission, which may underlie the rapid synaptotoxic effect of the peptide. Employing 
short peptides, we also sought for strategies, by which neuroprotection could be achieved. 
Therefore, we aimed to answer the following questions: 
• What effect does Api-42 exert on rapid synaptic function, more specifically on 
postsynaptic ionotropic glutamate receptors? 
• Which sequence of Ap 1 -42 might interfere with AP1 -42 induced neuromodulation? 
• Is there a difference between the mechanisms of protection of pentapeptides? 
• Would be feasible to apply the best neuroprotective pentapeptide intraperitoneally? 
• Does have endomorphin-2 a protective effect against Ap 1 -42? 
Since the sequence of endomorphin-2 (End-2, Tyr-Pro-Phe-Phe; YPFF) is highly 
similar to the sequence of a well known BSB, LPFFD, we tested whether the 
tetrapeptide protects neurons against Api-42 induced biological effects. 
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Materials and Methods 
In vivo extracellular single-unit electrophysiology 
Extracellular single-unit recordings were made in chloral hydrate-anesthetized male 
IWistar rats weighing 300-360g. After the head of the animal had been mounted in a stereotaxic frame, the skull was opened above the hippocampus (antero-posterior: -2.8 to -3.8 from bregma; lateral: 2 mm on either side from the midline), and the dura mater was carefully removed. Structures were localized according to the stereotaxic atlas of Paxinos and Watson (1986). All efforts were made to minimize animal suffering. The principles of laboratory 
animal care (NIH publication No. 85-23) and the protocol for animal care approved by the 
Hungarian Health Committee (1998) and the European Communities Council Directive of 24 
November 1986 (86/609/EEC) were followed. 
Extracellular recordings 
Single-unit activity was recorded extracellularly by means of a low-impedance (< 1 
MQ) 7 pm carbon fiber-containing microelectrode (Kation Scientific, Minneapolis, MN). The 
action potentials were amplified, filtered and monitored with an oscilloscope. A window 
discriminator was used for spike discrimination. The amplified signals were sampled and 
digitalized at 50 kHz. The number of action potentials per second was counted by the 
computer and peristimulus time histograms were calculated, displayed in line and digitally 
stored for off-line analysis. Iontophoretic drug delivery and experimental data collection were 
performed by a multifunction instrument control and data acquisition board (National 
Instruments PCI-1200) situated in a computer. 
The drug barrels of the combined recording/iontophoresis electrode contained one or 
other of the following solutions: 100 raM NMDA Na salt (pH 8.0), 10 mM AMPA 
hydrobromide (pH 8.0), 20 mM KA in 180 mM NaCl (pH 8.0), 2.5x10"4 M DAMGO/End-2 
dissolved in saline (pH 6.4), 2.5x10'4 M pentapeptide (RIIGL, LPYFDa, RVVIA, FRHDS) 
dissolved in pH 6.4 saline, a mixture containing Apl-42 (5x10~5 M) and DAMGO/End-2 
(2.5x10"4M), a mixture containing Apl-42 (5xl0"5M) and one of the above pentapeptides (pH 
6.4), 5xl0"5 M Api-42 (pH 6.4). The mixture solutions were stored for 24 h at 4 °C. To lessen 
the degree of aggregation, Api-42 and the mixture solutions were sonicated (Merck Eurolab 
Solutions 
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120 W apparatus) for 15 min prior to use. All substances were purchased from Sigma Aldrich, 
(Budapest, Hungary), with the exception of Api-42, End-2 and the pentapeptides, which were 
synthetized in-house by a solid-phase procedure involving the use of Wang resin and Fmoc 
chemistry. 
Fig.. 4,: Scanning electromicrograph of the Carbostar 7S multibarrel electrode tip. Courtesy 
ofKation Scientific. 
Iontophoresis 
Excitatory agents were ejected with negative iontophoretic currents ranging from 2 to 
100 nA. Retaining currents in the interval 2-21 nA of opposite direction were used. The 
pentapeptides, End-2 and DAMGO were ejected at +100 nA for 3 minutes, Apl-42 and the 
mixtures for 1 min at -0.5 pA. Cells were excited by the brief (5s) repetitive ejection of 
NMDA and AMPA or NMDA and KA. The ejection current was selected so that the 
maximum firing rate fell between 30 and 80 spikes/s. The interval between two excitation 
epochs was 120 s. When NMDA alone was used for excitation, ejection occurred every 
minute. The peristimulus time histograms of the neurons were recorded. After establishment 
of a stable control (at least four successive peaks), the solution to be examined was ejected. 
Data analysis 
Statistical evaluations were performed by using the total number of spikes evoked 
during each excitation epoch by iontophoretic application of an excitatory agent. The 
background neuronal discharge was calculated by averaging a 15s period of ongoing activity 
preceding each excitation epoch, and this value was subtracted from all evoked response^ 
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The total spike number during each excitation epoch was calculated and expressed as a 
percentage of the mean (± SEM), and compared statistically with the data obtained after 
peptide application by using one-way analysis of variance (ANOVA, with the Bonferroni test 
for post hoc analysis). A P value of < 0.05 was considered significant. 
In order to confirm the location of the cells under study, the last recording site was 
marked at the end of the experiment by ejecting Pontamine Sky Blue with 5 pA for 20 min. 
The brains were removed and fixed with a solution of 10% paraformaldehyde and glucose. 
Forty gm thick serial coronal sections were cut using a freezing-microtome and stained with 
neutral red. The marked recording positions were histologically determined in frontal frozen 
sections by means of stereotaxic coordinates 
Fig- 5.: Histological verification of the recording site. Forty-micrometer thick slices were 
prepared with a microtome and then stained with neutral red. Pontamine Sky Blue marks the 
position of the electrode tip in the CA1 hippocampal region. 
Inset: representative single-unit action potentials recorded from the marked site. 
Histology 
Results 
Effects of Api-42 on the ionotropic Glu receptor mediated neuronal firing 
Experiments were carried out on a total of 61 hippocampal CA1 neurons recorded 
from 45 anesthetized rats. All these cells, which had little or no spontaneous activity, 
responded to NMDA, AMPA or KA applied iontophoretically prior to the application of AJ31-
42. 
Effect of Afi 1-42 on the NMDA-evoked response 
We have examined the effect of A|31-42 ejection on the NMDA-evoked responses on 
one neuron, without utilizing other excitatory agent. NMDA was ejected at every minute. The 
percent change in the number of NMDA-evoked spikes after A01^12 was 267% ±19% (n = 
14) as compared with the pre-Api^!2 control. The enhancement of the NMDA triggered 
response peaked between 8 and 27 min and did not return to the control level within the 45-
min time-frame of the experiments, as described by (Molnar et al., 2004), although the level 
of responses had decreased to 155 ± 28% after 18 to 24 min in 5 cells of the 14. In contrast, 
iontophoresis of the saline without peptide caused no change in the baseline activity or in the 
NMDA-evoked firing rate (n = 6, data not shown). 
Afil-42-mediated effects on NMDA- and AMPA-evoked neuronal firing 
In the second set of experiments, 16 neurons were excited by the alternating ejection 
of NMDA and AMPA. The interval between each two excitation epochs was 120 s. Api-42-
containing solutions were ejected at -0.5 pA for 1 min. After a stable control period, Api-42 
was administered. As a result, the NMDA- evoked neuronal firing increased up to a maximum 
of 260±28%. The enhancement of neuronal firing became significant (P<0.05) following the 
second or third NMDA excitation (5-7 min after Apl-42 ejection), and the firing frequency 
remained at a high level throughout the timeframe of the experiment. In contrast, the AMPA 
responses decreased significantly after Api-42 application in all of the measured cells. Two 
types of cells were found on the base of temporal change of firing frequency. In 5 cells, the 
AMPA-mediated responses started to decrease only 23-25 minutes after Api-42 application, 
not following the temporal changes in the NMDA-evoked firing (n=5). Other cells responded 
to Api-42 with a sharp, immediate decrease in AMPA evoked firing (n=6), accompanied by 
the previously described trend of an increase in the NMDA-elicited responses. In both sets of 
cells, the AMPA responses almost completely disappeared in 35-37 min (9.5±5.5%; P<0.05). 
Iontophoresis of the vehicle alone (saline, pH 6.4) caused no change in the NMDA and 
AMPA-mediated responses (n=5; data not shown). 
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Fig. 6.: Effect of Aft 1-42 on the NMDA-evoked responses of a CA1 rat hippocampal neuron 
in vivo. A/31-42 (50 pM capillary concentration) application is denoted. The total number of 
spikes evoked during each epoch of excitation per minute before and after peptide 
application (A/31-42) was compared. Apl-42 was ejected at -0.5 pAfor 1 min. 
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NMDA/AMPA alternating ejection every 2 min 
Fig. 7.: Representative peristimulus histograms showing the effects of Apl-42 on the NMDA-
and AMPA-evoked firing on CA1 neurons in vivo. NMDA and AMP A were ejected at -46 nA 
and -87 nA (Panel A), and at -24 nA and -39 nA (Panel B), respectively. Api-42 was applied 
at -0 5 pA for 1 min. The interval between two excitation epochs was 120 s. Note the 
decrease in spontaneous activity of the cells after peptide application. 
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Apl-42-mediated effects on NMDA and KA-evoked neuronal firing 
In the third set of experiments, 19 neurons were excited with similar episodes of brief 
(5-s) iontophoretic ejection of NMDA and KA. As described in the previous section, the level 
of NMDA-triggered action potentials rose to a maximum of 268±35% in all of the recorded 
cells (P<0.05, n=14) following A(31-42 application. The firing enhancement remained at this 
level during the remainder of the experiment. As concerns the KA-mediated responses, two 
types of cells were found. In the first type, no significant change could be observed in the KA-
mediated responses after Api-42 application: the KA-evoked neuronal firing remained at the 
control level (109.5±9.5%, n=8). However, in 6 cells, the KA-mediated responses decreased 
immediately after Api-42 ejection to a level of 28±12% (P<0.05, n=6). Application of the 
vehicle without AP caused no change in the NMDA and KA-mediated responses (n=5; data 
not shown). 
'a. 
V ) 
> 
u c u 3 ZT 
ai 
1 / 0 " 
iso -
130 -
110 -
00 -
70 -
so -
30 -
10 -
170-
150-
130-
110-
90 -
70 -
50 -
30 -
10 -
A, 
NMDA ft 
KA • 
Api 42 
'• o • a t o ot 0 0 t o 0 
B, 
NMDA tf 
KA • 
A p l 42 
tM 0 • 
L-UJL 
cr • tr • tr • 
i . L L U L 
Ot tMtl • tl 
l i 
t o t tr • t i t t i t 
u L L 1 
QttJ t a t tr t 
NMDA/KA alternating ejection every 2 min 
F'g. 8.: Representative peristimulus time histograms of two CA1 neurons, displaying the 
effects of Af 1-42 on the NMDA- and KA-mediated neuronal firing in vivo. NMDA and KA 
Were ejected at -84 nA and -63 nA (Panel A), and at -41 nA and -59 nA (Panel B) 
respectively. Apl-42 was applied at -0.5 pAfor 1 min. Excitation occurred every 2 min AB1-
42 caused no change in the KA responses in the first group of cells (n=8, Panel A), while KA 
responses disappeared almost completely in the second group (n=6, Panel B) 
27 
Effects of LPYFDa and Aft 1-42 mixture on NMDA and AMPA-evoked neuronal firing 
To verify the Api-42 specificity in the attenuation of AMPA responses, we employed 
a protective pentapeptide, LPYFDa. It has been reported that this pentapeptide protects 
neurons against the fEPSP attenuating and cell-viability decreasing action of Api-42 in vitro 
(Szegedi et al, 2005a). A mixture of LPYFDa (2.5x10"4 M) and Apl-42 (5x10"5 M) was 
applied in a 5:1 molar ratio at -0.5 pA for 1 min. Ejection of this mixture did not significantly 
change the level of either the NMDA or the AMPA-evoked responses (n=6). The maximum 
in the NMDA-mediated responses was 115±12%, while that in the AMPA-elicited firing was 
125±18%. 
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Fig. 9.: A representative per ¡stimulus histogram of the effects of Apl-42 and an LPYFDa-
containing mixture on the NMDA (ejected at - 47 nA) and AMPA (ejected at - 82 nA)-evoked 
neuronal firing from the CAl region in vivo. The mixture was ejected for 1 min at -0.5 pA. 
Excitation occurred every 2 min. 
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Summary of evoked responses 
after ejection of Api -42 and LPYFDa 
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Fig. 10.: Summary of evoked responses 23-25 min after application of A/31-42 or Afil-
42/LPYFDa mixture. The labels represent the agonist employed (NMDA, AMP A or KA), 
while Afil-42 and LPYFDa refer to the peptides administered. The two sets of cells as 
concerns the changes in AMPA- and KA-evoked firing after Afil-42 ejection are denoted (I) 
and (II). Asterisks indicate significant differences from the pre-AfiI-42 control (ANOVA, 
P<0.05). 
API-42 derived pentanentides protect against Afll-42 induced enhancement of NMDA 
triggered firing 
Short peptide fragments of A(31-42 are thought to interfere with the aggregation 
properties of Ap peptides. Since the biological activity of Ap 1-42 is strongly dependent of its 
aggregation state, inhibiting aggregation would be a feasible way in the combat against 
Alzheimer's disease. Our aim was to find pentapeptides, which protect against the NMDA 
response enhancing effect of Api-42 in vivo, and to differentiate between the possible 
inhibitory mechanisms. For the identification of peptide recognition sites, our group has 
designed different pentapeptides spanning the entire Api-42 sequence. Peptide design was 
supported by theoretical considerations and our former results. Our research group found that 
AP31-35 (lie- Ile-Gly-Leu-Met; IIGLM) is neurotoxic (Penke and Baranyi, 1994), however, 
the tetrapeptide propionyl-Ile-Ile-Gly-Leu amide (Pr- IIGLa) protects glial and neuronal cells 
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from the toxic effect of Ap 1-42 (Laskay et al., 1997). Similarly, the C-terminal pentapeptide 
of A p l ^ 2 (Gly-Val-Val-Ile-Ala amide, GVVIAa), which is critical for Ap aggregation 
(Jarrett et ah, 1993), interferes with AP toxicity. In a neuronal viability test, this pentapeptide 
proved to be protective (Hetenyi et ah, 2002). Ap4-8 (Phe-Arg-His-Asp-Ser, FRHDS) is a 
possible ligand for integrin-like receptors (Lorenzo et ah, 2000; Sabo et ah, 1995) and we 
presume that this Ap fragment and its analogues might serve as inhibitors for the Ap-integrin 
interactions. On the basis of previous results, novel compounds of four pentapeptides 
(analogues of Ap4-8, 17-21, 30-34, and 38-42) were synthetized. One of them (Phe-Arg-
His-Asp-Ser amide, FRHDSa) is an integrin ligand analogue; Leu-Pro-Tyr-Phe-Asp amide 
(LPYFDa; (Datki et ah, 2004) is a slightly modified analogue of Soto's Leu-Pro-Phe-Phe-Asp 
(LPFFD). Arg-Ile-Ile-Gly-Leu amide (RIIGLa) and Arg-Val-Val-Ile-Ala amide (RVVIAa) 
are water-soluble analogues of the peptides that we earlier prepared and studied (propionyl-
Ile-Ile-Gly-Leu amide and Gly-Val-Val-Ile-Ala amide). In order to differentiate among the 
possible protective mechanisms, two kinds of ejection patterns were used. The pentapeptides 
were either co-iontophorised, or applied in mixture form with Api-42. Parallel with the in 
vivo studies, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and 
in vitro electrophysiological experiments were performed, however, only the in vivo studies 
are in the focus of the present thesis. 
H2N-DAE FRHDSGYEVHHQKLVFFAEDVGSNKGAIIGL MVGGVVIA-COOH 
FRHDSa LPYFDa RIIGLa RVVIAa 
Fig. 11.: Sequence of A/11-42 and the derived pentapeptides. FRHDSa (Af4-8), LPYFDa (an 
analogue of Af 17-21), RIIGLa (an Arg substitute of A/430-34) and RVVIA (an Arg substitute 
of A f38-42) were tested against A/31-42 induced enhancement in vivo. 
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Co-iontophoresis ofAf 1-42 and the individual pentapeptides 
When the individual pentapeptides were administered together with Api-42 (co-
iontophorized), the neuromodulatory effect of Apl-42 was decreased. FRHDSa (n = 8) and 
LPYFDa (n = 8) prevented the enhancement of the NMDA-induced responses caused by 
Apl-42, although a small increase could be observed after 15 min: the response maxima were 
150 ± 28% and 157 ± 37% (Apl^l2 response maximum was 267 ± 19%). Application of 
RIIGLa (n = 4), however did not significantly prevent the A p l - 4 2 induced enhancement of 
the responses: 30 min after ejection, the responses did not differ from those induced by A p l -
42. RVVIAa co-iontophoresis (n = 7) offered no prevention from the Apl-42 effect either. 
However, the responses after RVVIAa administration were enhanced up to a maximum of 
314 ± 48%, which was reached between 22 and 40 min after ejection. The individual 
pentapeptides alone did not change the NMDA-evoked firing rate (data not shown). 
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Fig. 12.: A representative peristimulus histogram of a co-iontophoretic application of the 
pentapeptide FRHDS and Apl-42. The CA1 neuron was excited by the repetitive ejection of 
NMDA (ejected at - 38 nA). FRHDS was ejected for 3 min at+100 nA, while Apl-42 for 1 min 
at -0.5 pA. Excitation occurred every min. 
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Fig. 13.: Summary of the effects of co-iontophorized pentapeptides on the enhancement of 
NMDA-evoked neural responses by Apl-42. After establishment of a stable control, a 
pentapeptide was ejected for 3 min, followed immediately by Apl-42 for 1 min. The effects are 
reported as percentages of the total spike number during each epoch of excitation before 
ejection of the peptides ± SEM. Asterisks denote statistical differences as compared with the 
data obtained after Apl-42 ejection (ANOVA, P < 0.05 level). The NMDA-evoked responses 
on CA1 hippocampal neurons were measured every minute; for better clarity, the figure 
presents only the data obtained every 5 min. 
Iontophoresis of the mixtures containing pentapeptide and Apl-42 
Some of the individual pentapeptides applied in mixtures with Ap 1-42 (in a 5:1 molar 
ratio) were also successful in preventing the Api-42 induced enhancement of the NMDA 
induced responses. FRHDSa proved to be inactive in these experiments: no significant 
difference was observed between the enhancing effect of Ap 1^12 and the mixture of Api-42 
and FRHDSa after 25 min (n = 13). The LPYFDa-containing mixture did not result in an 
NMDA-evoked response enhancement; this peptide fully prevented the neuromodulatory 
effect of AP 1-42 (n = 6). RIIGLa demonstrates a partial counteraction against Api-42: the 
maximum response was 174 ± 24% (n = 7). Similarly to the results of the coiontophoresis, 
RVVIAa was ineffective also in the mixture form (n = 6): the maximum firing rate was larger 
(317 ± 51%) than that induced by Apl-42 (267 ± 19%) between 17 and 25 min after ejection. 
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Fig. 14.: A representative peristimulus histogram of a pentapeptide/Afil-42 mixture 
application. LPYFDa/Apl-42 mixture solution was ejected for 1 min at -0.5 pA. The CA1 
neuron was excited by the repetitive ejection of NMDA (ejected at -21 nA). Excitation 
occurred every min 
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Fig. 15.; Summary of the effects of mixtures containing a pentapeptide and Ap 1-42 and of 
Apl-42 alone on the NMDA-evoked responses. The effects are reported as percentages of the 
total spike number during each epoch of excitation before ejection of the mixtures or Afl-42 
(±SEM). Asterisks denote statistical differences as compared with the data obtained after 
peptide ejection (ANOVA, P < 0.05 level). The NMDA-evoked responses on CA1 hippocampal 
neurons were measured every minute; for better clarity, the figure presents only data obtained 
every 5 min. 
34 
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300 T 
Fig. ¡6.: Summary of the maximum values of NMDA-evoked responses from Figs. 13 and 15, 
normalized by the control data (the total spike number during each epoch of excitation before 
peptide/mixture ejection). FRHDS exhibited protection on co-iontophoresis with A[31-42, 
RIIGL was effective in the mixture form, and LPYFDa proved to be protective in both 
application methods. Asterisks indicate significant differences as compared with the A/31-42-
inducedenhancement (Student's t test P < 0.05). 
Intraperitoneal administration of LPYFDa 
Our next aim was to elucidate, whether LPYFDa, the most effective protective 
pentapeptide, is capable of preventing Api-42 induced effects when administered 
intraperitoneally (i.p.). A control pentapeptide, pentaglycin (GGGGG) was used as control. 
First, we tried to find a stable single-unit activity within the CA1 region. After 
reaching a stable control sequence for NMDA induced firing, we ejected Api-42, just as 
described previously. At the same time, LPYFDa was injected intraperitoneally. Since one 
recording session lasted for about 35 minutes, and activity was recorded from 4 rats, we were 
not able to standardize the recording time points. Instead, we pooled the data from every 40 
minutes after i.p. administration. 
All neurons recorded 0 min or 40 min after i.p. administration of the peptides showed 
a clear Api-42 induced NMDA-response enhancement. In contrast, the NMDA-induced firing 
frequency of cells of LPYFDa treated animals did not rise after Api-42 ejection between 80 
and 200 minutes after i.p. administration (137 ± 11%, 120 ±14%, 120 ± 12%, 125 ± 11%; 
35 
n=3, 4, 4 and 3 respectively). However, GGGGG treatment did not manage to protect against 
Apl-42 induced response enhancement at this time interval (n=3). The excitatory effect of 
Api-42 returned, when peptide ejection occurred 240 minutes after i.p. administration of 
LPYFDa. GGGGG administration was ineffective in preventing Apl-42 induced excitation. 
Maximum responses of NMDA-evoked firing 
Min after i.p. administration 
Fig. 17,: Summary of the maximum values of NMDA-evoked responses, normalized by the 
control data (the total spike number during each epoch of excitation before A/31-42). LPYFDa 
protected against the NMDA-response enhancement effect of Af 1-42 between 80 and 200 min 
after i.p. administration of the pentapeptide. The control pentapeptide, pentaglycin was not 
able to interfere with Afil-42 induced excitation. Asterisks indicate significant differences 
(Student's t test P < 0.05). 
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Endomorphin-2, an endogenous tetrapeptide protects against AB1-42 in vivo 
A recently isolated endogenous tetrapeptide, endomorphin-2 (End-2, YPFF, Tyr-Pro-
Phe-Phe) (Zadina et al., 1997) shows high structural similarity with LPFFD: the C-terminal 
tripeptide sequence (PFF) of End-2 perfectly matches with the middle tripeptide sequence of a 
well-known BSB peptide, LPFFD. In addition, the high endomorphin-2 containing central 
nervous system areas (Martin-Schild et al., 1999) seem to be unaffected both in human 
Alzheimer's disease and in transgenic animals (Games et al., 1995; Hsiao et al., 1996; 
Joachim et al., 1991). Those areas, which suffer massive cell loss in AD, including the 
hippocampal formation and neocortex, show no or little End-2 like immunreactivity. 
Therefore it is intriguing to suppose, that this endogenous tetrapeptide might have some 
protective action against Api-42. End-2 possesses some antioxidant effect alone (Lin et al., 
2003), and protective action through the activation of the mu-opioid receptor (MOR) (Iglesias 
et al., 2003; Liao et al., 2003), therefore we used a synthetic peptidomimetic agonist of the 
same receptor, (D-Ala2, N-Me-Phe4, Gly5-ol)-enkephalin (DAMGO) as a control substance. 
Effects of Endomorphin-2 and DAMGO 
End-2 alone was ejected for 3 minutes after establishing a stable evoked neuronal 
firing (control). The NMDA-evoked responses increased up to a maximum of 162±14% (n=9, 
P<0.05), which proved to be significant comparing to the control response-level. Response 
enhancement lasted for 18-20 minutes, and then the level of triggered neuronal firing returned 
to control level. DAMGO application for 3 minutes resulted in similar significant response 
enhancement to 167±5% (n=5, P0.05) . However, the evoked responses did not return to the 
control level within the time frame of the experiment, the enhancement proved to be long 
lasting. Application of the vehicle had no effect on the rate of evoked neuronal firing (n=6, 
data not shown). 
Effect of mixtures containing Afl-42 and End-2 or Afl-42 and DAMGO 
The peptide mixtures were administered iontophoretically for one minute at -0.5pA. In 
that way, only the negatively charged Api-42 was ejected, End-2/DAMGO could not leave 
the micropipette, unless absorbed on the surface of different Apl-42 assemblies. Application 
of the End-2 and Api-42 mixture did not result in enhancement of the NMDA responses: the 
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level of neuronal firing remained at 115±21% (n=6). In contrast, ejection of the DAMGO and 
Api-42 containing solution enhanced NMDA-evoked firing. The maximum response to 
269±37% remained, and it did not return to control level (n=6, P<0.05). 
Co-iontophoresis of Apl-42 and End-2 or Apl-42 and DAMGO 
In order to elucidate the protective mechanism of End-2 against the effect of Api-42, 
co-iontophoretic administration was used. End-2 and DAMGO were ejected right before Api-
42 application with the same current and time frame as described above, to ensure the 
effective concentration in the close vicinity of the neuron. In that way, p-opioid receptors will 
be activated, and the drugs will not exert their putative protective effect on the surface of 
aggregated Apl-42 species. After ejection of End-2, immediately Api-42 was applied. The 
maximum NMDA-evoked response reached 348±65%, and the enhancement remained during 
the measurements (n=7, P<0.05). Co-iontophoresis of DAMGO with Apl-42 resulted in 
similar response enhancement. The maximum evoked response was 238±37%, and the effect 
did not diminish during the time frame of the experiment (n=6, /><0.05). 
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Fig- 18.: Peristimulus histograms representing the effect of Ap 1-42 (A), endomorphin-2 (B), 
endomorphin-2 and Ap 1-42 co-iontophoresis (C) and endomorphin-2 and AP 1-42 containing 
mixture (D) on the NMDA-induced neuronal firing recorded from CA1 hippocampal neurons 
in vivo. Arrows denote the time of peptide application. 
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Maximum resnonses of NMD A evoked neuronal firing 
# 
Fig. 19.: Summary of the maximum values of NMDA-evoked responses from CA1 neurons in 
| vivo, normalized by the control data. End-2 (n=9) and DAMGO (n=5) were applied for 3 
minutes. Afl-42 (n=14) and the mixtures (n=6 for End-2 and n=6for DAMGO) were applied 
for 1 minute. At co-iontophoretic application, following 3 minute End-2/DAMGO (n=7 and 
n=6, respectively) ejection, A/31-42 was applied for I minute. The total number of spikes 
i evoked during each epoch of excitation per minute before and after peptide application (A/31-
42 and/or End-2/DAMGO) was compared. Asterisk denotes significant difference compared to 
A/31-42 data, while # marks difference from control (ANOVA, P < 0.05). 
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Discussion 
Rapid effects of AB1-42 on the ionotropic glutamate receptor mediated neuronal 
firing 
Microiontophorised Api-42 exerted divergent effects on the NMDA-, AMP A- and 
KA-evoked firing of CA1 neurons in vivo. NMDA-evoked responses were enhanced, AMPA-
triggered firing was attenuated, while the frequency of KA-induced action potentials were 
either diminished or remained unchanged. 
NMDA receptor activation by AP is well documented in previous studies (Harkany et 
al., 2000; Wu et al., 1995), however, we were the first to demonstrate this phenomenon in 
vivo. NMDA overactivation may lead to increased Ca2+ influx, which causes excitotoxicity. In 
support of this, NMDA antagonists (e.g. Memantine®) were proved to be protective against 
Ap on neurons and in AD patients (Harkany et al., 1999; Miguel-Hidalgo et al., 2002; Ruther 
et al., 2000). Although NMDA receptor overactivation seems to play a critical role in the 
pathogenesis of AD, little is known about the exact mechanism. Ap may directly bind to the 
NMDA receptor complex, as was demonstrated by (Cowburn et al., 1997), and this interaction 
might increase the single-channel conductivity or the opening probability. Another possibility 
is that Apl-42 triggers a yet unknown cascade by activating an extracellular protein, which 
may result in the alternation of NMDA receptor-subunit phosphorilation level (Sze et al., 
2001). The latter seems more plausible, because a pentapeptide, which is supposed to bind to 
the integrin receptors, is capable of protecting against Apl-42 induced NMDA receptor 
excitation (see later). In addition, NMDA mediated firing-enhancement emerged only 8-12 
minutes after Apl-42 ejection, while compounds, acting directly on a receptor must exert 
their effects more rapidly. Therefore, a direct modulation of NMDA receptor complex by 
Apl-42 is quiet unlikely. 
Since there is no data in the literature, which suggest Apl-42-AMPA receptor 
binding, diminishing of the AMPA-mediated signals may be due to an altered intracellular 
regulatory mechanism. A crucial step in the induction of NMDA-independent long term 
potentiation (LTP) of synaptic plasticity is the trafficking of AMPA receptors into the 
postsynaptic site, increasing the concentration of glutamate-responsive elements directly at 
the neuron-neuron junction (Kakegawa et al., 2004; Kolleker et al., 2003). As these 
mechanisms are closely related to the intact cytoskeleton, and given the wealth of data 
indicating Api-42 interference with the normal cytoskeletal working (e.g. (Datki et al., 2004; 
Gamblin et al., 2003)), such altered mechanisms cannot be ruled out. Alternatively, the 
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changed function of the C-jun N-terminal kinases (JNK)-mediated AMPA receptor recycling 
pathway represents another possibility of Api-42 interference. Wang et al. (Wang et al., 
2002a) found that JNK inhibitors rescue the Ap-induced inhibition of LTP. Further, a 
decrease in the AMPA-mediated responses can explain the lack of LTP seen in Api-42-
treated animals. AMPA receptors are known to be essential for the NMDA-dependent LTP in 
the CA1 region. GluR-A (a subunit of the AMPA receptor) knock-out adult rats do not 
develop LTP in the CA1 (Jensen et al., 2003). Moreover, LTP could not be elicited in the 
presence of an AMPA antagonist in in vitro experiments (Debray et al., 1997). A synaptic 
function impairment emerges before the physical integration of the synapses (Yao et al., 
2003) and Ap pathology (Ye et al., 2004) during the onset of AD. As a consequence, we 
propose that the hypofunction of AMPA, and possibly the altered working of KA receptors, 
contributes significantly to the LTP blockade caused by Apl-42. It has been suggested that 
the selective neuronal loss in the CA1 region in AD is due to the selective expression of Ca2+-
permeable AMPA channels (Blanchard et al., 2004). Our results do not support this 
hypothesis, because AMPA-mediated responses had disappeared almost completely from all 
of the recorded cells. However, the cells remained active: the NMDA responses increased 
after Apl-42 application. The discrepancy between the two results may be explained; 
Blanchard et al. utilized an in vitro Ca2+ influx measurement, where they specifically blocked 
all AMPA receptors on cultured neurons. In this way, antagonising of AMPA receptors may 
cause a complete blockade in the working of NMDA receptors, because the blocking Mg2+ 
ions remain in the NMDA ion channels (see (Freitas da Rocha et al., 2001) for review). In 
contrast, under our in vivo circumstances, the modulating effects of the ejected AJ31-42 
emerges only at the near vicinity of the electrode that do not include the entire membrane 
surface of the CA1 neuron; each of the ejected compounds (NMDA, AMPA, KA, Apl-42) 
reach only a limited surface of the observed cell. Therefore, due to the constant "synaptic 
bombardment", the membrane potential of the neuron may reach the threshold, where Mg2+ 
ions exit from the NMDA ion channels allowing NMDA-evoked neuronal firing. 
Our results reveal that the changes in the NMDA- and AMPA-evoked responses do 
not follow the same temporal pattern. We used a mixture of mature Apl-42 fibrils and 
protofibrils, as revealed by transmission electron microscopy (TEM) images (Szegedi et al., 
2005b). One study (Ye et al., 2004) suggests that the modulation of NMDA and non-NMDA 
glutamate receptors by Apl-42 is dependent on the aggregation state. Protofibrils enhance 
NMDA receptors, while fibrils act on non-NMDA receptors. However, both aggregation 
states increased the neuronal excitability in patch-clamp experiments and the different 
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aggregation states of Aft may be responsible for the differences in temporal change. Further 
studies are needed to elucidate the exact mechanisms of this finding. 
The effects of Ap 1-42 on the KA-induced firing distinguished two groups of cells. In 
the first group, AP did not change the KA responses. However, the NMDA responses 
enhanced, and Ap therefore acted on the neurons. In the other group, Ap sharply decreased 
the KA-evoked responses, similarly to the AMPA-elicited firing. KA receptors are localized 
presynaptically and postsynaptically in the CA1 region, and it is therefore difficult to fully 
explain the above found results. Additionally, KA in a relatively high concentration has been 
reported to act on AMPA receptors. To make the situation even more complicated, recent 
papers report on the possible metabotropic effects of KA receptors (Rodriguez-Moreno and 
Lerma, 1998) (Frerking et al., 2001). 
Ap attenuates the field excitatory postsynaptic potential (fEPSP) in the hippocampal 
region and in the primary motor cortex both in vitro and in vivo (Stephan et al., 2001; Szegedi 
et al., 2005a). Our results show that, despite the activation seen in the NMDA-evoked firing, 
the AMPA- and even KA-induced responses massively decreased. The sum of these changes 
in the working of fast-acting excitatory ionotropic channels points to a net decrease in the 
neuronal excitability and synaptic activity, which is presumed to be measured by fEPSP 
induction. 
API-42 derived pentapeptides protect neurons against AB1-42 
The protective effects of 5 selected pentapeptides derived from Api-42 towards the 
neuromodulatory effects of Ap 1^12 were studied. 
LPYFDa proved to be protective against iontophoresed Api-42. It prevented both the 
NMDA-evoked firing enhancement, and AMPA responses attenuation. This peptide, an 
analogue of a well-known BSB (LPFFD), can be bound with high affinity to the Apl—42 
monomer (Hetenyi et al., 2002). Therefore, we hypothesize that a rapid and strong binding 
occurs between the pentapeptide and Apl-42 assemblies, preventing further interaction with 
the cells. Accordingly, LPYFDa was protective both on co-iontophoretic administration and 
by ejection in a mixture with Api-42. 
The arginin substitute of C-terminal fragment of Api-42, RVVIA exhibited some 
protection against Api-42 toxicity in the MTT assay (Hetenyi et al., 2002; Szegedi et al., 
2005a), this effect was not significant, and the same peptide was found to be inactive against 
microiontophorised Ap in vivo. 
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RIIGL was also protective in MTT assay and in in vitro electrophysiological studies 
(Szegedi et al., 2005a). This peptide displayed protective action only in the mixture form 
(after preincubation with Api-42) and proved to be inactive when simultaneously ejected (co-
iontophoresis) in in vivo electrophysiological studies. We assume that the pentapeptide binds 
to AP, however the time of contact between Api^ l2 and RIIGL is relatively short in the co-
iontophoretic experiments. The pentapeptide probably cannot cover the surface of Ap 
assemblies, owing to the short contact. During preincubation, the pentapeptide molecules 
have enough time to bind to the surface of Api-42, neutralizing its neuromodulatory effects. 
FRHDS, a protective agent in MTT assay, was effective in in vivo 
electrophysiological experiments only when ejected by co-iontophoresis to the cells; its 
preincubation with Api-42 (mixture form) did not provide protective action. This difference 
in effects may not serve as an unquestionable evidence of different protective mechanism, but 
may indicate a different site of action. Literature data reveal that Arg-His-Asp-Ser (RHDS) 
and similar peptides bind to the integrin-like receptors of the cell surface (Ghiso et al., 1992; 
Sabo et al., 1995; Saporito-Irwin and Van Nostrand, 1995). We presume that Phe-Arg-His-
Asp-Ser acts as a competitive inhibitor by binding to the integrins of the cellular membrane, 
inhibiting further interaction of the integrin like receptors with the Apl -42 aggregates. Since 
the inhibition of this interaction may prevent the neuromodulatory effects of Api-42, further 
investigation and experiments may yield a novel therapeutic direction in the treatment of AD. 
We conclude from our results that LPYFDa and RIIGL protect neurons from the 
modulatory effect of Apl-42 by binding to Ap. FRHDS probably acts rather as integrin-type 
receptor-binding ligand. RVVIA proved to be practically inactive against the 
neuromodulatory effects of Api-42. 
Intraneritoneallv administered LPYFDa protects against AB1-42 induced neuronal 
excitation 
Intraperitoneal^ administered LPYFDa was able to defend against Api-42 induced 
neuronal excitation. The temporal window of effectiveness was relatively wide (between 80 
and 200 min after administration), since the compound was not optimized for enzyme 
resistance and blood-brain barrier permeability. The emerging point of the neuroprotective 
effect of the administrated compound is in good correlation with other studies, which 
described similar intraperitoneal central nervous system (CNS) targeting peptide 
administration (Li et al., 2006; Tohyama et al., 2004; Wang et al., 2002b). Pentaglycin, the 
control peptide did not display protection. 
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An endogenous pentapeptide. endomorphin-2 protects neurons against AB1-42 
The amyloid induced enhancements of NMDA-evoked responses were also 
diminished by End-2. This protective effect was not mediated through the activation of mu-
opioid receptor (MOR), because DAMGO, a synthetic MOR agonist was not able to attenuate 
the Api-42 mediated effect. Results of the two kinds of in vivo iontophoretic experiments 
("mixture" and "co-iontophoresis") provided additional evidence, that the activation of mu-
opioid receptors does not yield protection against Apl-42. Co-iontophoretic application of 
Apl-42 with either End-2 or DAMGO resulted in NMDA-induced response-enhancement, 
similar to the effect of p-amyloid. However, when Apl-42 was preincubated with End-2, no 
p-amyloid induced enhancement could be measured, similarly with LPYFDa and RIIGL. In 
co-iontophoretic experiments, the ejection of MOR agonists preceded Api-42 application in 
order to activate the p-receptors. In contrast, at application of the mixture solutions, the pH 
values and the ejection polarities were chosen in that way, that only Apl-42 and the possibly 
bound End-2 and DAMGO could leave the capillary. Under these conditions presumably no 
significant MOR activation occurred due to the ejection of the mixtures. Since the sequence of 
End-2 resembles to LPFFD and LPYFDa, a similar protective mechanism is assumed. The 
tetrapeptide binds to the surface of aggregated Api-42, as revealed by radioligand binding 
studies and circular dichronism experiments (Szegedi et al., 2006), however, it does not 
behave as a BSB compound. According to transmission electron microscopy and quasi-light 
scattering studies, End-2 does not interfere with the aggregation of Apl-42 (Szegedi et al., 
2006). Therefore, the most plausible way of protection is the surface coverage of Api-42 by 
the tetrapeptide, preventing further detrimental interaction of the formed complex with the 
cells. 
Being an endogenous substance, End-2 might play a role in the actual AD progression, 
and possibly assent to the area selective cell loss seen in the disease and transgenic animals. 
Central nervous system areas, with high End-2 content were found to be unaffected by Ap 
induced damage (Games et al., 1995; Hsiao et al., 1996; Joachim et al., 1991). Those areas, 
which suffer cell loss in AD, including the hippocampal formation and neocortex, show no or 
little End-2 like immunreactivity. Only a few endogenous molecules have been reported or 
suggested to have protective effect against p-amyloid, i.e. taurine (Louzada et al., 2004) and 
kynurenic acid (Sawateeva et al., 1999), which target the excitotoxic imbalance either by y-
aminobutyric acid A ( G A B A A ) receptor activation, or by NMDA receptor inhibition. Shifting 
the net level of neuronal excitability towards inhibition attenuates Ca2+ entry. Decreased 
intracellular Ca2+ level provides less probability of apoptotic cascade initiation. Another 
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endogenous compound, melatonin has a more complex neuroprotective mechanism. In 
addition to its antioxidant properties, it also binds to G A B A a receptor (Louzada et al., 2004). 
Additionally, melatonin blocks fibrillogenesis of Api-42 in vitro (Pappolla et al., 1998). 
Endomorphin-2 may join to this list of neuroprotective endogenous compounds, however it 
has a more distinct and direct neuroprotective action against Apl-42, namely it blocks the 
harmful amyloid-cell interaction. 
The effect of mu-opioid receptor activation on the NMDA evoked neuronal firing 
indicated that the action potentials of pyramidal cells were recorded. The distribution of MOR 
in the hippocampus displays cell type specificity: only the GABA-ergic interneurons express 
this type of inhibitory, metabotropic receptor (Drake and Milner, 1999; Drake and Milner, 
2002). Therefore, excitation after End-2 and DAMGO ejection indicates a disinhibitory 
mechanism (McQuiston and Saggau, 2003): p-receptor bearing interneurons might be 
inhibited by agonists, resulting in an attenuation of the inhibitory input to the pyramidal cells, 
increasing their excitability has increased. 
f 
Perspectives for future drug development for AD treatment 
Current drugs against AD treatment furnish only symptomatic treatment and have their 
limitations. Compounds targeting Ap directly offer protection from the majority of p-amyloid-
induced neuromodulatory effects and may serve as leads for further drug development. Our 
most promising agent, LPYFDa is capable of penetrating the blood-brain barrier and protect, 
when administered intraperitoneally. However, the pentapeptide, may be optimized for having 
longer defensive period, therefore it may serve as a lead compound for future drug 
development. 
Our other promising compound is End-2, which, as being a tetrapeptide, may have better 
bioavailability and more favorable pharmacokinetics than the pentapeptides. Since it is an 
endogenous substance, one may speculate to increase its level in the organism would be 
beneficial for patients suffering from AD. However, approaches aimed to increase End-2 level 
in the brain presumably would not offer rational treatment of AD patients. The activation of 
h-opioid receptors increases the net excitability in the CA1 region, and may result in focal 
epileptic seizures (McQuiston and Saggau, 2003). Consequently, in the treatment of 
Alzheimer's disease, the sequence of End-2 is what may be exploited as a lead sequence for 
development of peptidomimetic drugs that will not activate p-opioid receptors. 
Summary 
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First, we have demonstrated a rapid deleterious effect of aggregated Apl-42 on the 
normal excitatory synaptic function. Ejected Apl-42 enhanced NMDA-induced neuronal 
firing, while AMPA evoked responses were diminished. KA receptor mediated firing 
remained unchanged, or attenuated. These results may explain the ffiPSP decreasing and LTP 
attenuating effect of Api-42. In addition, these phenomena might form the basis of the 
cognitive decline in early AD, where neuron loss is low. In the light of these results, the usage 
of drugs acting on AMPA receptors may be feasible in that stage of the disease. 
Second, we have tested 4 pentapeptides derived from Api-42 against Ap induced 
neuronal excitation. By using two patterns of peptide ejection, we have shown different 
putative protective mechanisms of these pentapeptides. RIIGL and LPYFD were effective in 
the mixture form with Apl-42, indicating a direct binding between the two compounds. In 
contrast, FRHDS displayed a competitive inhibitor-like effect, preventing the interaction of 
AP 1-42 with the cells. 
Third, we have proved that i.p. administration of the most potent neuroprotective 
Pentapeptide, LPYFDa may offer protection against Apl-42 in a relatively moderate temporal 
Period. By optimizing the structure of this pentapeptide, a more effectiveness could be 
reached. 
Fourth, we have shown that an endogenous tetrapeptide, End-2 defends against Api-
42 elicited NMDA response enhancement. Since the tetrapeptide was only effective in the 
mixture form with Api-42 and DAMGO did not display protection, End-2 defends in a MOR 
independent manner. 
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